ICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICI

This study tests whether re-starting immunotherapy (checkpoint inhibitors like pembrolizumab or nivolumab) helps patients with advanced non-small cell lung cancer (NSCLC) who had a long response to their first course of immunotherapy but have since progressed. **You may be eligible if...** - You are between 18 and 80 years old with confirmed stage III or IV non-small cell lung cancer - You completed at least 35 cycles of first-line immunotherapy (with or without chemotherapy) or had stable disease for at least 2 years — and have now progressed - You have at least one measurable tumor on scans - Your general health score (ECOG) is 0–2 **You may NOT be eligible if...** - Your cancer has a treatable mutation (like EGFR, ALK, ROS1) that has specific targeted therapy options - You had serious immune-related side effects from prior immunotherapy - You have active autoimmune disease - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.